Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Shareholders Right Agreement just filed

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 15, 2022 12:11pm

96 Views

Post# 34606488

RE:RE:RE:RE:RE:RE:Shareholders Right Agreement just filed

I wouldn't worry too much. It's fairly rare for hostiles in biotech because you'd need to understand the science in depth prior to doing anything. In some ways it helps us since it creates a buffer time period where other players can come in in look --provided there's a reason to look first!! We need to get there before even bothering to worry about this. But it's not necessarily bad and a rare feat in biotech anyway.